The CAR-T cell therapy Aucatzyl was approved for relapsed or refractory B-cell precursor acute lymphoblastic leukemia based ...

Researchers found that neural crest stem cells are uniquely capable of reprogramming, challenging current reprogramming ...

FDA approves Autolus Therapeutics' Aucatzyl for adults with relapsed or refractory B-cell precursor acute lymphoblastic ...

The investigators added that inflammation and demyelination were reduced, while axonal density oligodendrocytes, ...

The FDA approved obecabtagene autoleucel (obe-cel; Aucatzyl) for treating relapsed or refractory B-cell precursor acute ...

In both pediatric and adult patients, cranial radiation therapy causes a debilitating cognitive decline that is poorly understood and currently untreatable. This decline is characterized by ...

We have demonstrated that cranial irradiation markedly alters hippocampal progenitor-cell biology. Within the irradiated hippocampus, precursor proliferation is reduced by 62% and neuro-genesis is ...

A team of biochemists at the University of California, San Diego, working with a group of biochemical engineers from the ...

Chinese research team has fabricated a perovskite-silicon tandem solar cell without a hole transport layer (HTL) in the ...

NEW DELHI: One patient suffering from severe medical conditions for years has provided diagnosis for 30 people whose similar ...

Autolus Therapeutics (AUTL) announces the U.S. FDA has granted marketing approval for Aucatzyl for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic ...

for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia, or ALL. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try ...